Literature DB >> 10068397

Hypocalcemia associated with alendronate.

D H Schussheim, T P Jacobs, S J Silverberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10068397     DOI： 10.7326/0003-4819-130-4-199902160-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  Seizures after alendronate.

Authors:  Richard J Maclsaac; Ego Seeman; George Jerums
Journal:  J R Soc Med       Date:  2002-12       Impact factor: 5.344

2.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

Review 3.  Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.

Authors:  Yoon Kong Loke; Vinodh Jeevanantham; Sonal Singh
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?

Authors:  Christian Horst Tonk; Sarah Hani Shoushrah; Patrick Babczyk; Basma El Khaldi-Hansen; Margit Schulze; Monika Herten; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 5.  Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?

Authors:  Ignacio-Osoitz Leizaola-Cardesa; Antonio Aguilar-Salvatierra; Maximino Gonzalez-Jaranay; Gerardo Moreu; María-José Sala-Romero; Gerardo Gómez-Moreno
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-03-01

6.  Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database.

Authors:  Florence T Wang; Fei Xue; Yan Ding; Eva Ng; Cathy W Critchlow; David D Dore
Journal:  BMC Health Serv Res       Date:  2018-04-10       Impact factor: 2.655
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.